EDIT Stock Editas Medicine (EDIT, $1.34) Stochastic Oscillator left the oversold zone on January 03, 2025

GET DAILY SIGNALS

Get AI intraday signals

EDIT - Editas Medicine

Stochastic signal

View

Odds of UP Trend

Price: $1.34

Daily change: +$0.03 (+2.29%)

Daily volume: 2.5M

Capitalization: $110.6M

Industry: Biotechnology

EDIT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for EDIT turned positive on December 31, 2024. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EDIT's RSI Indicator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EDIT entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.630) is normal, around the industry mean (15.511). P/E Ratio (0.000) is within average values for comparable stocks, (87.884). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.767). EDIT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.782) is also within normal values, averaging (271.338).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.